| P2093 | author name string | G. Powis | |
| P2860 | cites work | Combination chemotherapy with adriamycin and streptozotocin; I. Clinical results in patients with advanced sarcoma | Q28319582 |
| | Phase I studies on chlorozotocin | Q28319830 |
| | Microsomal metabolism of nitrosoureas | Q28323092 |
| | Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans | Q28324506 |
| | Vincristine-Induced Quadriparesis | Q28330613 |
| | Allopurinol kinetics | Q28332005 |
| | Initial clinical studies with bruceantin | Q33469676 |
| | Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion | Q33486268 |
| | Phase I evaluation of dianhydrogalactitol (NSC-132313) | Q33505009 |
| | Lidocaine Pharmacokinetics in Advanced Heart Failure, Liver Disease, and Renal Failure in Humans | Q34216672 |
| | Clearance concepts in pharmacokinetics | Q34218381 |
| | Influence of route of administration on drug availability | Q34226637 |
| | Biliary excretion of vincristine | Q34263753 |
| | Glomerular filtration rate and creatinine clearance | Q34448915 |
| | The plasma half-life of antipyrine in chromic uraemic and normal subjects | Q34451714 |
| | A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol | Q34515217 |
| | Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients | Q34517614 |
| | Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration | Q34518084 |
| | Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia | Q34518096 |
| | Metabolism of amylobarbitone in patients with chronic liver disease | Q35174112 |
| | 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate | Q35198092 |
| | Renal Failure, Drug Pharmacokinetics and Drug Action | Q35372914 |
| | Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion | Q36042825 |
| | Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy | Q38537378 |
| | Kinetics of intravenous melphalan | Q38537678 |
| | Hydroxylation of the carcinostatic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) by rat liver microsomes. | Q53816232 |
| | Pathophysiological Factors Influencing Drug Kinetics | Q54097059 |
| | Renal clearance of oxipurinol, the chief metabolite of allopurinol | Q57480150 |
| | Influence of acute viral hepatitis on phenytoin kinetics and protein binding | Q58817425 |
| | Pharmacokinetics of oral and intravenous fluorouracil in humans | Q59289870 |
| | Plasma half-life of cytosine arabinoside in patients with leukaemia--the effect of uridine | Q66842856 |
| | High-pressure liquid chromatographic analysis of ftorafur and its metabolites in biological fluids | Q66880486 |
| | Clinical Pharmacokinetics of Cyclophosphamide | Q66897379 |
| | Pharmacokinetics of Creatinine in Man and Its Implications in the Monitoring of Renal Function and in Dosage Regimen Modifications in Patients with Renal Insufficiency | Q66934771 |
| | Synthesis and biologic evaluation of major metabolites of N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea | Q66960048 |
| | The disposition of cyclophosphamide in a group of myeloma patients | Q66992161 |
| | Some observations on the human pharmacology of methotrexate | Q67051755 |
| | Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man | Q67314024 |
| | Hydrolysis and Protein Binding of Melphalan | Q67318972 |
| | Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease | Q67326600 |
| | Quantitative Assessment of Hepatic Function by Breath Analysis after Oral Administration of [^14C]aminopyrine | Q67347874 |
| | High-dose intravenous and hepatic artery infusions of thymidine | Q67391377 |
| | Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect | Q67462261 |
| | Kinetics of gallium nitrate, a new anticancer agent | Q67463129 |
| | Kinetics of cis-dichlorodiammineplatinum | Q67467904 |
| | Pharmacology of the nitrosoureas: an overview | Q67525059 |
| | Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay | Q67540791 |
| | The pharmacokinetics of [3H]-vincristine in man | Q67674473 |
| | Clinical effects and pharmacokinetics of different dosage schedules of adriamycin | Q67764510 |
| | Mechanism of action and pharmacology studies with DTIC (NSC-45388) | Q67768784 |
| | Pharmacokinetics of Cytembena in chronic renal impairment | Q67772665 |
| | Commentary: a physiological approach to hepatic drug clearance | Q43996648 |
| | Physiologic disposition of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (Me CCNU) in man. | Q44027814 |
| | Daunorubicin metabolism in acute nonlymphocytic leukemia | Q44179770 |
| | Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance | Q44201992 |
| | Pharmacokinetics of Cyclophosphamide in Renal Failure | Q44318026 |
| | Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model | Q44430214 |
| | Intrahepatic Portasystemic Shunting in Cirrhotic Patients | Q44552245 |
| | Clinical and pharmacological evaluation of triazinate in humans | Q44629003 |
| | Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance | Q44804450 |
| | Cisplatin pharmacokinetics in a patient with renal dysfunction | Q44872612 |
| | Bilary disposition of adriamycin | Q44912291 |
| | Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding | Q47840215 |
| | A STUDY OF PLASMA PROTEIN VARIATIONS IN SURGICAL PATIENTS. | Q47889575 |
| | The effect of neoplastic and allied diseases on the concentrations of the plasma proteins | Q47977567 |
| | Clinical pharmacology of cyclophosphamide | Q48012175 |
| | Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule | Q48590767 |
| | STUDIES OF FLUORINATED PYRIMIDINES. XVIII. THE DEGRADATION OF 5-FLUORO-2'-DEOXYURIDINE AND RELATED COMPOUNDS BY NUCLEOSIDE PHOSPHORYLASE. | Q52163797 |
| | Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration | Q38537846 |
| | Bleomycin pharmacokinetics in man. I. Intravenous administration | Q38537946 |
| | Clearance and biologic half-life as indices of intrinsic hepatic metabolism | Q39321643 |
| | Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function | Q39431438 |
| | Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay | Q39465511 |
| | Antineoplastic drugs: clinical pharmacology and therapeutic use. | Q39496661 |
| | Studies on the clinical pharmacology of bleomycin | Q39512795 |
| | Protein Binding and Kinetics of Drugs in Liver Diseases | Q39620831 |
| | Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans | Q39693243 |
| | The clinical pharmacology of methotrexate.new applications of an old drug | Q39716312 |
| | Clinical Pharmacokinetics of Methotrexate1 | Q39720628 |
| | Effects of Renal Disease upon Drug Disposition | Q39780234 |
| | Combination chemotherapy with adriamycin and streptozotocin; II. Clinicopharmacologic correlation of augmented adriamycin toxicity caused by streptozotocin | Q39788530 |
| | Use of Serum Creatinine Concentrations to Determine Renal Function1 | Q39806214 |
| | Preliminary Pharmacokinetics of Streptozotocin, an Antineoplastic Antibiotic | Q39821483 |
| | Hepatic First-pass Metabolism in Liver Disease | Q39842380 |
| | Drug Kinetics and Hepatic Blood Flow | Q39842386 |
| | m-AMSA and PALA: two new agents in cancer chemotherapy | Q39849979 |
| | Pharmacokinetics of the protein antitumor antibiotic neocarzinostatin after bolus injection in humans | Q39879766 |
| | Experimental and clinical studies on the formation of antibodies to neocarzinostatin, a new protein antibiotic | Q39884741 |
| | Streptozotocin for malignant insulinomas and carcinoid tumor. Report of eight cases and review of the literature | Q39898958 |
| | Albumin synthesis (second of two parts). | Q39913712 |
| | Liver disease and drug therapy | Q39947640 |
| | Pharmacokinetics of cyclophosphamide in man | Q39986730 |
| | Intraarterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma.A clinical and pharmacology report | Q40164606 |
| | Drug pharmacokinetics in cardiac and hepatic disease | Q40285169 |
| | Drug therapy in renal failure | Q40285180 |
| | Hepatic disease and drug pharmacokinetics | Q40294490 |
| | Dose-dependent pharmacokinetics and cancer chemotherapy | Q40313416 |
| | The disposition of ftorafur in rats after intravenous administration | Q40342314 |
| | Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia | Q40484946 |
| | Clinical studies with rubidazone | Q40599792 |
| | Drug dosage in renal disease | Q40640491 |
| | Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity | Q40655039 |
| | Kinetics and Mechanisms of Drug Action on Microorganisms XXIII: Microbial Kinetic Assay for Fluorouracil in Biological Fluids and Its Application to Human Pharmacokinetics | Q40830418 |
| | GLC Determination for Ftorafur in Biological Fluids | Q40830427 |
| | Phase I study on bruceantin administered on a weekly schedule | Q40851300 |
| | Phase I clinical evaluation of anguidine | Q40953808 |
| | Clinical aspects of the excretion of alkylating cyclophosphamide metabolites in the urine of tumor bearing patients | Q40959469 |
| | Metabolism and Disposition of Baker's Antifolate (NSC-139105), Ftorafur (NSC-148958), and Dichlorallyl Lawsone (NSC-126771) in Man | Q40965407 |
| | Pharmacokinetics and metabolism of ftorafur in man | Q41017536 |
| | Disposition of 5-fluorouracil after intravenous bolus doses of a commercial formulation to cancer patients | Q41056416 |
| | Evidence for toxicologic activity of ftorafur independent of conversion to 5-fluorouracil | Q41094238 |
| | Clinical toxicologic and pharmacologic studies of gallium nitrate | Q41117027 |
| | Decreased half life of cyclophosphamide in patients under continual treatment | Q41445391 |
| | Determinants of serum antipyrine half-lives in patients with liver disease | Q41516235 |
| | Selective lethal effect of thymidine on human and mouse tumor cells | Q41956427 |
| | A clinical-pharmacological evaluation of hepatic arterial infusion of adriamycin | Q42122134 |
| | Clinical toxicity of chloridazepoxide and diazepam in relation to serum albumin concentration: A report from the Boston collaborative drug surveillance Program | Q42236052 |
| | Nephrotoxicity of nitrosoureas | Q42269168 |
| | Pharmacokinetics of vindesine and vincristine in humans | Q42596669 |
| | A phase I study of cytembena | Q43308621 |
| | Renal function and the rate of disappearance of methotrexate from serum | Q43492583 |
| | The effect of phenobarbital on cyclophosphamide antitumor activity | Q67796403 |
| | Pharmacokinetics of the fluoropyrimidines: implications for their clinical use | Q67809648 |
| | Phase I studies with Baker's Antifol (BAF) (NSC 139105) | Q67831177 |
| | Systemic methotrexate toxicity. A pharmacological study of its occurrence after intrathecal administration in a patient with renal failure | Q67861390 |
| | Clinical antitumor activity and toxicity of streptozotocin (NSC-85998) | Q68699417 |
| | The Biotransformation of Cyclophosphamide in Man: Analysis of the Variation in Normal Subjects | Q68941255 |
| | Estimation of Drug Elimination in Renal Failure | Q68966729 |
| | Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease | Q69216617 |
| | Phenobarbital effects on cyclophosphamide pharmacokinetics in man | Q69461828 |
| | Pharmacokinetics of methotrexate | Q69559055 |
| | Pharmacokinetics and metabolism of adriamycin in man | Q69559062 |
| | Hepatic toxicity of nitrosourea analogues | Q69813137 |
| | The physiological disposition of the carcinostatic 1,3-bis(2-chloroethyU-l-nitrosourea (BCNU) in man and animals | Q69973848 |
| | Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy | Q70086060 |
| | Drug elimination and apparent volume of distribution in multicompartment systems | Q70423307 |
| | Clinical kinetics on intact cisplatin and some related species | Q70660296 |
| | Determination of N-(Phosphonacetyl)-l-Aspartic acid (PALA) in plasma and urine by high pressure liquid chromatography | Q70760212 |
| | Pharmacokinetics of methotrexate administered via the hepatic artery | Q70868039 |
| | Kinetics of cyclophosphamide biotransformation in vivo | Q71127536 |
| | Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans | Q71127551 |
| | Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation | Q71140139 |
| | Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans | Q71180637 |
| | The effect of organic acids on renal clearance of methotrexate in man | Q71232539 |
| | Quantitation by gas chromatography-chemical ionization-mass spectrometry of phenylalanine mustard in plasma of patients | Q71235547 |
| | Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes | Q71263732 |
| | Studies with allopurinol in patients with impaired renal function | Q71346976 |
| | Pharmacokinetics of gallium nitrate in man | Q71355979 |
| | Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study | Q71356139 |
| | Clinical pharmacologic effects of thymidine plus 5-FU | Q71507707 |
| | Clinical pharmacology of IMPY by radioimmunoassay | Q71507715 |
| | Influence of range of renal function and liver disease on predictability of creatinine clearance | Q71509238 |
| | Phase I trial of pentamethylmelamine: a clinical and pharmacologic study | Q71566429 |
| | Pharmacologic studies of tritiated cytosine arabinoside (NSC-63878) in children | Q71744774 |
| | Albumin metabolism in the nephrotic syndrome in adults | Q72364696 |
| | Correlation of serum creatinine concentration and kanamycin half-life. Therapeutic implications | Q72526873 |
| | Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis | Q72844481 |
| | Phase II evaluation of triazinate in patients with metastatic lung cancer | Q72878603 |
| | Phase II trial of methyl-GAG in advanced renal cancer | Q72893995 |
| | (131-I)ALBUMIN TURNOVER AND LOSS OF PROTEIN INTO THE SPUTUM IN CHRONIC BRONCHITIS | Q76945346 |
| | THE PHYSIOLOGIC DISPOSITION OF 5-FLUOROURACIL AND 5-FLUORO-2'-DEOXYURIDINE IN MAN | Q76959399 |
| | The fate of antipyrine in man | Q80647000 |
| | Renal excretion of sulphadimidine in normal and uraemic subjects | Q93724994 |
| | Gentamicin dosages for renal insufficiency. Adjustments based on endogenous creatinine clearance and serum creatinine concentration | Q93816637 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | oncology | Q162555 |
| | pharmacokinetics | Q323936 |
| P304 | page(s) | 85-124 | |
| P577 | publication date | 1982-06-01 | |
| P1433 | published in | Cancer Treatment Reviews | Q1955762 |
| P1476 | title | Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs | |
| P478 | volume | 9 | |